Allogeneic Hematopoietic Stem Cell Transplantation for Solid Tumors

Mudhafar Zubair Alqasim, Alauldeen

	Allogeneic Hematopoietic Stem Cell Transplantation for Solid Tumors
Iraqi Journal of Cancer and Medical Genetics
Article 1, Volume 9, Issue 1, 2016, Pages 68-73
Author
Alauldeen Mudhafar Zubair Alqasim
Abstract
Hematopoietic stem-cell transplantation (HSCT) refers to a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of cytotoxic drugs, with or with- out whole-body radiation therapy. Stem cells may be obtained from the transplant recipient (autologous HSCT) or can be harvested from a donor (allogeneic HSCT). Stem cells may be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. The perception of the mechanisms through which malignant cells are eradicated following allogeneic hematopoietic cell transplantation (HCT) has evolved substantially over the past four decades. No longer merely thought of as a means to rescue hematopoietic function following myeloablative conditioning, allogeneic transplantation is now known to be a powerful type of immunotherapy capable of curing patients with other-wise fatal malignant diseases. This conceptual evolution has trans- lated into a diversi cation of the indications for allotransplants and led to the development of reduced intensity transplant ap- proaches whose bene cial antineoplastic effects occur as a consequence of the transplanted donor immune system. Recently, investigators have begun to test whether non-hematologic malignancies might likewise be susceptible to allogeneic immune attack.
Keywords
cancer; Solid Tumors; Stem Cell Transplantation

Statistics Article View: 187 PDF Download: 43